Lancet Research Summaries Now Span Key Cancers

Clinicians and patients following breast, lung, prostate and other cancers can now find Lancet evidence organized by disease area.

Updated on Nov. 12, 2026 in Cancer

Isometric editorial illustration of unmarked hardcover volumes stacked and fanned into piles beside a clear beaker of amber liquid, evoking organized medical research evidence.
The Lancet and Conexiant have launched Research in Context, a program organizing Lancet research into disease-area summaries that now include several cancers. AI Illustration. Upload story photo >

Conexiant and Elsevier signed a licensing agreement naming Conexiant a commercial licensing partner for The Lancet: Research in Context, a digital program that organizes Lancet-published research by disease area. The program launched across 10 therapeutic areas, including several cancers, so clinicians and patients following these fields can find evidence summaries more easily.

Why it matters

The initiative is designed to make published research easier to find and to help healthcare professionals apply new evidence to clinical decisions. For readers following cancer care, it means that findings from major journals will be packaged with overviews of what the evidence shows and what it means for practice.

The figure reported is the launch scope of 10 therapeutic areas, with no outcome data on reach or readership yet available. The announcement does not include study-level results, since the program is a publishing and access initiative rather than a clinical trial.

The players

Conexiant

Conexiant is a commercial licensing partner that expands the reach of medical and scientific content, and it previously collaborated with Elsevier on society marketing and member engagement.

Elsevier

Elsevier is a global publisher of scientific and medical research, and it publishes The Lancet journals whose content is featured in the Research in Context program.

The Lancet

The Lancet is a long-established medical journal group whose primary research journals are the source of the evidence summarized in the Research in Context program.

The details

Each Research in Context feature gives an overview of the available evidence, explains what new findings contribute, and outlines implications for clinical practice, policy, and future research. The platforms group this work by disease area and link readers directly to the original Lancet articles, so the summaries serve as a guide rather than a replacement for the primary studies. Related email newsletters and engagement programs extend the reach of this material to healthcare professionals.

Timeline

  1. The Research in Context program launched across 10 therapeutic areas in the week before the licensing agreement was announced.

  2. The licensing agreement between Conexiant and Elsevier was announced on November 12, 2026.

Health Landscape

The program sits alongside the Lancet's primary research journals as a way to turn individual studies into disease-area overviews for clinicians and researchers. It reflects a broader push in medical publishing to help readers navigate large volumes of evidence across cancers and chronic conditions.

If you are following a cancer diagnosis or treatment, the new digital summaries may make it easier to see how recent evidence fits together, which can be a useful starting point for questions to bring to your care team. Any decision about your own treatment is best discussed with your physician, who can weigh the research against your individual situation.

The takeaway

Making published research easier to navigate by disease area can help clinicians and patients keep pace with evidence in cancer care. When reviewing new findings with your doctor, asking how a study's results apply to your situation is a practical step worth taking.

Further reading

For more on how new research is reshaping treatment options, explore our Cancer coverage.

Source note: This article includes information reported by Knowledgespeak.